Fixed trandolapril and verapamil SR combination effectiveness in arterial hypertension patients

Aim. To study the effectiveness, rates of target blood pressure (BP) level achievement, and safety of a fixed-dose trandolapril and verapamil SR combination (Tarka) in patients with Stage I-II arterial hypertension (AH). Material and methods. The study initially included 100 AH patients; 7 dropped out, and 4 were excluded due to inclusion criteria violation. The study protocol was completed by 89 participants (36% men, 64% women), aged 27-74 years (mean age 56,6 10,8 years), with mean AH duration of 9,1 8 years. After 3-14-day wash-out period, clinical mean systolic BP (SBP clin.) level was 158,1 +/- 9,3/95,1 +/- 8,0 mm Hg, and heart rate (HR) level - 75,2 +/- 7,4 bpm. BP level corresponded to Stage I AH in 40,5% of the patients, and to Stage 11 AH - in 59,5%. Eighty five per cent of the participants received anti hypertensive medications, 17% had Type 2 diabetes mellitus (DM-2), 20% were smokers. Results. In all patients, Tarka therapy (2/180 mg/d) was associated with adequate BP reduction. Antihypertensive effect reached its maximum at Week 4 of the treatment. Twelve-week therapy resulted in significant decrease in BP clin., (Delta=-28,9 +/- 11,0/-18,4 +/- 8,1; p < 0,001) and HR (Delta=-6,0 +/- 6,6; p < 0,0001). Target SBP, DBP or SBP+DBP levels were achieved in 82%, 96%, and 80%, respectively. In DM-2 patients, target BP level was achieved in 71%. According to 24-hour BP monitoring data, after 12 weeks of treatment, BP was normalized in 68 participants: in 88% - for SBP, in 99% - for DBP, and in 88% - for both SBP and DBP. In all patients, the treatment was well tolerated; adverse effects (A-E) were registered in 9 individuals only. Conclusion. Good antihypertensive effectiveness of fixed trandolapril and verapamil combination facilitated target BP level achievement in 80% of the patients, with low AE rates. Therefore, the medication could be recommended at initial treatment stage.